Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

329.98 +1.05 (+0.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
44 45 Next >
Stocks Snap Losing Streaks as VIX Inches Lower
Stocks were able to brush off interest rate hike concerns and a grim guidance warning from Microsoft on Thursday. 
Via Talk Markets
Oncolytics Reports Partnering With Biopharma Industry Leaders To Fast-Track Immunotherapy Treatment
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.74% on an annualized basis producing an average annual return of 10.5%. Currently, Amgen has a market capitalization of... 
Via Benzinga
Mirati Therapeutics Plunges As Its Hopes To Take On Amgen In Lung Cancer Crash
Mirati is unlikely to carve out share with a drug that didn't differentiate, analysts say. 
Via Investor's Business Daily
Quant Ratings Updated on 75 Stocks
I decided to revise my Portfolio Grader recommendations for 75 big blue chips -- of those 75, 24 stocks were updated to a buy. 
Via InvestorPlace
Analyst Ratings for Amgen
Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter: 
Via Benzinga
7 Retirement Stocks to Buy to Turbocharge Your Savings
The best offense is a good defense., Here are seven retirement stocks to buy that combine modest growth with safe dividends. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses? 
Via Investor's Business Daily
7 Dividend Stocks to Boost Your Retirement Savings
This is a very good time to look for quality foundational stocks that not only have growth potential but are solid dividend stocks, too. 
Via InvestorPlace
Peering Into Amgen's Recent Short Interest
Amgen's (NASDAQ:AMGN) short percent of float has fallen 3.7% since its last report. The company recently reported that it has 20.75 million shares sold short, which is 3.9% of all... 
Via Benzinga
5 Beaten-Down Blue-Chip Stocks to Buy Now
These are the best blue-chip stocks to buy now. MMM, AMGN, BA, JPM, and MSFT can make great investments in the coming months. 
Via InvestorPlace
NASDAQ: AMGN Investor Notice: Investigation over Possible Securities Laws Violations by Amgen Inc.
San Diego, CA -- (SBWIRE) -- 05/11/2022 -- An investigation was announced for investors of Amgen Inc. (NASDAQ: AMGN) shares over potential securities laws violations by Amgen Inc. 
Via SBWire
Executives Sell More Than $220M Of 3 Stocks
US stock futures traded higher on this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading. 
Via Benzinga
Markets Sell Off Following Last Week's Federal Reserve Decision
U.S. indices fell sharply again Monday as stocks continued to sell off following last week’s Fed rate hike decision. A gain in Treasury yields has also weighed on technology and growth stocks. 
Via Benzinga
This Is What Whales Are Betting On Amgen
A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 21 strange trades. 
Via Benzinga
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in... 
Via Talk Markets
Markets Close Turbulent Week On A Down Note
The S&P 500 traded lower in a roller coaster week on Wall Street as investors digested another Federal Reserve interest rate hike and a mixed batch of earnings reports. 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
7 Defensive Dividend Healthcare Stocks to Buy Now
As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. 
Via InvestorPlace
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Ongoing Investigation Alert: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Analyzing Amgen's Short Interest
Amgen's (NASDAQ:AMGN) short percent of float has fallen 7.95% since its last report. The company recently reported that it has 22.52 million shares sold short, which is 4.05% of... 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
Here's How Much $100 Invested In Amgen 10 Years Ago Would Be Worth Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.04% on an annualized basis producing an average annual return of 12.67%. Currently, Amgen has a market capitalization of... 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
44 45 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback